Effect of glutathione liposomes on diabetic nephropathy based on oxidative stress and polyol pathway mechanism

A novel antioxidant glutathione liposomes (GSH-LIP) were prepared and applied for diabetic nephropathy therapy. GSH-LIP not only improve the bioavailability and antioxidant capacity of glutathione to scavenge redundant ROS inducing by oxidative stress, but also effectively inhibit the activity of AR and sorbitol accumulation in polyol pathway. The imaging in vivo showed that GSH-LIP could target kidney and significantly improve renal pathology. GSH-LIP may become a new AR inhibitor and antioxidant, which provides a new theoretical basis for the study of drugs for therapy diabetic nephropathy.

Automated summary

The novel antioxidant glutathione liposomes (GSH-LIP) show promise as a new therapeutic option for diabetic nephropathy by improving bioavailability, antioxidant capacity, and targeting renal pathology.